Oncotarget. 2024 May 7;15:288-300. doi: 10.18632/oncotarget.28583.ABSTRACTPURPOSE: Sequential PET/CT studies oncology patients can undergo during their treatment follow-up course is limited by radiation dosage. We propose an artificial intelligence (AI) tool to produce attenuation-corrected PET (AC-PET) images from non-attenuation-corrected PET (NAC-PET)...

Oncotarget. 2024 May 7;15:285-287. doi: 10.18632/oncotarget.28528.NO ABSTRACTPMID:38712739 | DOI:10.18632/oncotarget.28528

Oncotarget. 2024 May 3;15:275-284. doi: 10.18632/oncotarget.28582.ABSTRACTSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and COVID-19 infection has led to worsened outcomes for patients with cancer. SARS-CoV-2 spike protein mediates host cell infection and cell-cell fusion that causes stabilization of tumor suppressor p53 protein. In-silico...

Oncotarget. 2024 Apr 8;15:248-254. doi: 10.18632/oncotarget.28579.ABSTRACTAcute myeloid leukemia (AML) is characterized by the rapid proliferation of mutagenic hematopoietic progenitors in the bone marrow. Conventional therapies include chemotherapy and bone marrow stem cell transplantation; however, they are often associated with poor prognosis. Notably,...

Oncotarget. 2024 Mar 19;15:238-247. doi: 10.18632/oncotarget.28567.ABSTRACTA clinical trial was conducted to assess the feasibility of enrolling patients with Stage II or III hormone receptor positive (HR+)/HER2-negative breast cancer to pre-operative dual PD-L1/CTLA-4 checkpoint inhibition administered prior to neoadjuvant chemotherapy (NACT). Eight...

Oncotarget. 2024 Mar 15;15:232-237. doi: 10.18632/oncotarget.28569.ABSTRACTHere, I suggest that while first-line osimertinib extends median progression-free survival (PFS) in EGFR-mutant lung cancer compared to first-generation TKIs, it reduces individual PFS in 15-20% of patients compared to first-generation TKIs. Since detecting a single resistant...